Timing of oral contraceptive use and the risk of breast cancer in BRCA1 mutation carriers

Breast Cancer Research and Treatment

Volumn 143, Issue 3, 2014, Pages 579-586

  Kotsopoulos, Joanne ^a   Lubinski, Jan ^b   Moller, Pal ^c   Lynch, Henry T ^d   Singer, Christian F ^e   Eng, Charis ^f   Neuhausen, Susan L ^g   Karlan, Beth ^h   Kim Sing, Charmaine ⁱ   Huzarski, Tomasz ^b   Gronwald, Jacek ^b   McCuaig, Jeanna ^j   Senter, Leigha ^k   Tung, Nadine ^l   Ghadirian, Parviz ^m   Eisen, Andrea ⁿ   Gilchrist, Dawna ^o   Blum, Joanne L ^p   Zakalik, Dana ^q   Pal, Tuya ^r   Sun, Ping ^a   Narod, Steven A ^a   more..

^a WOMEN S COLLEGE HOSPITAL   (Canada)

^b POMERANIAN MEDICAL UNIVERSITY   (Poland)

^c OSLO UNIVERSITY HOSPITAL   (Norway)

^d CREIGHTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIV KLIN FÜR FRAUENHEILKUNDE   (Austria)

^f LERNER RESEARCH INSTITUTE   (United States)

^g CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^h CEDARS SINAI MEDICAL CENTER   (United States)

ⁱ BRITISH COLUMBIA CANCER AGENCY   (Canada)

^j UNIVERSITY OF TORONTO   (Canada)

^k OHIO STATE UNIVERSITY   (United States)

^l BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^m CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

ⁿ DEPARTMENT OF RADIATION ONCOLOGY   (Canada)

^o UNIVERSITY OF ALBERTA   (Canada)

^p BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^q BEAUMONT HOSPITAL   (United States)

^r H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

more..

Author keywords

BRCA1; Breast cancer; Oral contraceptives

Indexed keywords

ADULT; AGE FACTORS; BRCA1 PROTEIN; BREAST NEOPLASMS; CASE-CONTROL STUDIES; CONTRACEPTIVES, ORAL; FEMALE; GENETIC ASSOCIATION STUDIES; HETEROZYGOTE; HUMANS; MIDDLE AGED; MUTATION; RISK FACTORS;

EID: 84894057159     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-013-2823-4     Document Type: Article

References (32)

1. Antoniou A et al (2003) Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 72(5):1117-1130
2. Narod SA (2010) BRCA mutations in the management of breast cancer: the state of the art. Nat Rev Clin Oncol 7(12):702-707
3. Kotsopoulos J et al (2005) Age at menarche and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. Cancer Causes Control 16(6):667-674
4. Gronwald J et al (2006) Influence of selected lifestyle factors on breast and ovarian cancer risk in BRCA1 mutation carriers from Poland. Breast Cancer Res Treat 95(2):105-109
5. Chang-Claude J et al (1997) Modifying effect of reproductive risk factors on the age at onset of breast cancer for German BRCA1 mutation carriers. J Cancer Res Clin Oncol 123(5):272-279
6. Jernstrom H et al (2004) Breast-feeding and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst 96(14):1094-1098
7. Kotsopoulos J et al (2012) Oophorectomy after menopause and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. Cancer Epidemiol Biomarkers Prev 21(7):1089-1096
8. Kotsopoulos J et al (2007) Age at first birth and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. Breast Cancer Res Treat 105(2):221-228
9. Cullinane CA et al (2005) Effect of pregnancy as a risk factor for breast cancer in BRCA1/BRCA2 mutation carriers. Int J Cancer 117(6):988-991
10. Moorman PG et al (2010) Evaluation of established breast cancer risk factors as modifiers of BRCA1 or BRCA2: a multi-center case-only analysis. Breast Cancer Res Treat 124(2):441-451
11. Eisen A et al (2008) Hormone therapy and the risk of breast cancer in BRCA1 mutation carriers. J Natl Cancer Inst 100(19):1361-1367
12. Rebbeck TR et al (2005) Effect of short-term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol 23(31):7804-7810
13. Russo J et al (1981) Influence of age and parity on the susceptibility of rat mammary gland epithelial cells in primary cultures to 7,12-dimethylbenz(a) anthracene. In Vitro 17(10):877-884
14. Narod SA et al (2002) Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst 94(23):1773-1779
15. Iodice S et al (2010) Oral contraceptive use and breast or ovarian cancer risk in BRCA1/2 carriers: a meta-analysis. Eur J Cancer 46(12):2275-2284
16. Moorman PG et al (2013) Oral contraceptives and risk of ovarian cancer and breast cancer among high-risk women: a systematic review and meta-analysis. J Clin Oncol 31(33):4188-4198
17. Cibula D et al (2011) Tubal ligation and the risk of ovarian cancer: review and meta-analysis. Hum Reprod Update 17(1):55-67
18. Collaborative Group on Hormonal Factors in Breast Cancer (1997) Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Collaborative Group on Hormonal Factors in Breast Cancer. Lancet 350(9084):1047-1059
19. Gierisch JM et al (2013) Oral contraceptive use and risk of breast, cervical, colorectal, and endometrial cancers: a systematic review. Cancer Epidemiol Biomarkers Prev 22(11):1931-1943
20. Zhu H et al (2012) Oral contraceptive use and risk of breast cancer: a meta-analysis of prospective cohort studies. Eur J Contracept Reprod Health Care 17(6):402-414
21. Nelson HD et al (2012) Risk factors for breast cancer for women aged 40 to 49 years: a systematic review and meta-analysis. Ann Intern Med 156(9):635-648
22. Hilakivi-Clarke L, de Assis S, Warri A (2013) Exposures to synthetic estrogens at different times during the life, and their effect on breast cancer risk. J Mammary Gland Biol Neoplasia 18(1):25-42
23. Gaffield ME, Culwell KR, Ravi A (2009) Oral contraceptives and family history of breast cancer. Contraception 80(4):372-380
24. Phipps AI et al (2011) Reproductive history and oral contraceptive use in relation to risk of triple-negative breast cancer. J Natl Cancer Inst 103(6):470-477
25. Dolle JM et al (2009) Risk factors for triple-negative breast cancer in women under the age of 45 years. Cancer Epidemiol Biomarkers Prev 18(4):1157-1166
26. Ma H et al (2010) Use of four biomarkers to evaluate the risk of breast cancer subtypes in the women's contraceptive and reproductive experiences study. Cancer Res 70(2):575-587
27. Bronson RA (1981) Oral contraception: mechanism of action. Clin Obstet Gynecol 24(3):869-877
28. Gaspard UJ et al (1983) Plasma hormone levels in women receiving new oral contraceptives containing ethinyl estradiol plus levonorgestrel or desogestrel. Contraception 27(6):577-590
29. Fortner RT et al (2012) Association between reproductive factors and urinary estrogens and estrogen metabolites in premenopausal women. Cancer Epidemiol Biomarkers Prev 21(6):959-968
30. Isaksson E et al (2001) Effects of oral contraceptives on breast epithelial proliferation. Breast Cancer Res Treat 65(2):163-169
31. Garcia y, Narvaiza D et al (2008) Effect of combined oral contraceptives on breast epithelial proliferation in young women. Breast J 14(5):450-455
32. Hunter DJ et al (1997) Reproducibility of oral contraceptive histories and validity of hormone composition reported in a cohort of US women. Contraception 56(6):373-378